{"transactions":[{"id":932308,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T21:05:05.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":600000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001706847-26-000002","document":"form4-01232026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000170684726000002/form4-01232026_040101.xml","form_type":"4"}},{"id":1289542,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:37:18.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001415889-25-002494","document":"form4-01312025_090114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002494/form4-01312025_090114.xml","form_type":"4"}},{"id":1289541,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2025-01-31T21:37:18.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":121522,"source":{"system":"sec-edgar","filing":"0001415889-25-002494","document":"form4-01312025_090114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002494/form4-01312025_090114.xml","form_type":"4"}},{"id":1640989,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:35:28.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":537000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":537000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":537000},"source":{"system":"sec-edgar","filing":"0001415889-24-003963","document":"form4-02152024_100218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924003963/form4-02152024_100218.xml","form_type":"4"}},{"id":1778937,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T21:26:23.000Z","date":"2023-09-17","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":1000000,"derivative":{"exercise_price":3.55,"expiration_date":"2033-09-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001415889-23-013339","document":"form4-09182023_090915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923013339/form4-09182023_090915.xml","form_type":"4"}},{"id":1778936,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2023-09-18T21:26:23.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":5208,"price":3.6,"value":18748.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023."}],"balance_after":46522,"source":{"system":"sec-edgar","filing":"0001415889-23-013339","document":"form4-09182023_090915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923013339/form4-09182023_090915.xml","form_type":"4"}},{"id":1810626,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-10T16:11:04.000Z","date":"2023-08-08","kind":"exercise","planned":true,"acquired":false,"shares":2714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":242286,"derivative":{"exercise_price":0.3,"expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":2714},"source":{"system":"sec-edgar","filing":"0001562180-23-006271","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023006271/primarydocument.xml","form_type":"4"}},{"id":1810625,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-10T16:11:04.000Z","date":"2023-08-08","kind":"exercise","planned":true,"acquired":false,"shares":57286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":57286},"source":{"system":"sec-edgar","filing":"0001562180-23-006271","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023006271/primarydocument.xml","form_type":"4"}},{"id":1810624,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T16:11:04.000Z","date":"2023-08-08","kind":"sale","planned":true,"acquired":false,"shares":2714,"price":2.02,"value":5482.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001562180-23-006271","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023006271/primarydocument.xml","form_type":"4"}},{"id":1810623,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T16:11:04.000Z","date":"2023-08-08","kind":"exercise","planned":true,"acquired":true,"shares":2714,"price":0.3,"value":814.2,"ownership":{"direct":true},"balance_after":118714,"source":{"system":"sec-edgar","filing":"0001562180-23-006271","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023006271/primarydocument.xml","form_type":"4"}},{"id":1810622,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T16:11:04.000Z","date":"2023-08-08","kind":"sale","planned":true,"acquired":false,"shares":57286,"price":1.9986,"value":114491.7996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $1.98 and a high of $2.06. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001562180-23-006271","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023006271/primarydocument.xml","form_type":"4"}},{"id":1810621,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T16:11:04.000Z","date":"2023-08-08","kind":"exercise","planned":true,"acquired":true,"shares":57286,"price":0.39,"value":22341.54,"ownership":{"direct":true},"balance_after":173286,"source":{"system":"sec-edgar","filing":"0001562180-23-006271","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023006271/primarydocument.xml","form_type":"4"}},{"id":1852351,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:41:19.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":8929,"price":2.1,"value":18750.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 15, 2023."}],"balance_after":41314,"source":{"system":"sec-edgar","filing":"0001415889-23-009959","document":"form4-06162023_090615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923009959/form4-06162023_090615.xml","form_type":"4"}},{"id":1889104,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:09:34.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008246","document":"form4-05182023_010525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008246/form4-05182023_010525.xml","form_type":"4"}},{"id":1944545,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-20T20:33:03.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":11228,"price":1.67,"value":18750.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 16, 2023."}],"balance_after":32385,"source":{"system":"sec-edgar","filing":"0001415889-23-005218","document":"form4-03202023_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923005218/form4-03202023_080357.xml","form_type":"4"}},{"id":2081727,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-20T02:16:51.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":8424,"price":1.5,"value":12636.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022."}],"balance_after":21157,"source":{"system":"sec-edgar","filing":"0001415889-22-012797","document":"form4-12202022_021242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922012797/form4-12202022_021242.xml","form_type":"4"}},{"id":2134038,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-20T16:05:38.000Z","date":"2022-10-18","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":57286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-22-007293","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022007293/primarydocument.xml","form_type":"4"}},{"id":2134037,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-20T16:05:38.000Z","date":"2022-10-18","kind":"sale","acquired":false,"shares":15000,"price":11.6993,"value":175489.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $11.51 and a high of $11.94. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001562180-22-007293","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022007293/primarydocument.xml","form_type":"4"}},{"id":2134036,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-20T16:05:38.000Z","date":"2022-10-18","kind":"exercise","acquired":true,"shares":15000,"price":0.39,"value":5850.0,"ownership":{"direct":true},"balance_after":131000,"source":{"system":"sec-edgar","filing":"0001562180-22-007293","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022007293/primarydocument.xml","form_type":"4"}},{"id":2152519,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-22T16:40:10.000Z","date":"2022-09-20","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":72286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-22-006791","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022006791/primarydocument.xml","form_type":"4"}},{"id":2152518,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T16:40:10.000Z","date":"2022-09-20","kind":"sale","acquired":false,"shares":20000,"price":13.5022,"value":270044.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $13.12 and a high of $13.92.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001562180-22-006791","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022006791/primarydocument.xml","form_type":"4"}},{"id":2152517,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T16:40:10.000Z","date":"2022-09-20","kind":"exercise","acquired":true,"shares":20000,"price":0.39,"value":7800.0,"ownership":{"direct":true},"balance_after":136000,"source":{"system":"sec-edgar","filing":"0001562180-22-006791","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022006791/primarydocument.xml","form_type":"4"}},{"id":2155781,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-19T21:09:25.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":4294,"price":2.62,"value":11250.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 15, 2022."}],"balance_after":12733,"source":{"system":"sec-edgar","filing":"0001415889-22-009773","document":"form4-09192022_020914.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922009773/form4-09192022_020914.xml","form_type":"4"}},{"id":2179129,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-18T16:06:10.000Z","date":"2022-08-16","kind":"exercise","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":92286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-22-006214","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022006214/primarydocument.xml","form_type":"4"}},{"id":2179128,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T16:06:10.000Z","date":"2022-08-16","kind":"sale","acquired":false,"shares":80000,"price":12.6363,"value":1010904.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $12.40 and a high of $13.02.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001562180-22-006214","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022006214/primarydocument.xml","form_type":"4"}},{"id":2179127,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T16:06:10.000Z","date":"2022-08-16","kind":"exercise","acquired":true,"shares":80000,"price":0.39,"value":31200.0,"ownership":{"direct":true},"balance_after":196000,"source":{"system":"sec-edgar","filing":"0001562180-22-006214","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022006214/primarydocument.xml","form_type":"4"}},{"id":2227961,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T20:27:17.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":5542,"price":2.03,"value":11250.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022."}],"balance_after":8439,"source":{"system":"sec-edgar","filing":"0001415889-22-006741","document":"form4-06172022_010656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922006741/form4-06172022_010656.xml","form_type":"4"}},{"id":2234211,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T23:08:04.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-22-006519","document":"form4-06132022_040655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922006519/form4-06132022_040655.xml","form_type":"4"}},{"id":2324641,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T20:05:27.000Z","date":"2022-03-18","kind":"grant","acquired":true,"shares":2897,"price":3.02,"value":8748.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022."}],"balance_after":2897,"source":{"system":"sec-edgar","filing":"0001415889-22-003185","document":"form4-03182022_040310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922003185/form4-03182022_040310.xml","form_type":"4"}},{"id":2407952,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-02-08T16:05:58.000Z","date":"2022-02-07","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying this option have vested."}],"balance_after":172286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-22-001223","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022001223/primarydocument.xml","form_type":"4"}},{"id":2407951,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-08T16:05:58.000Z","date":"2022-02-07","kind":"exercise","acquired":true,"shares":15000,"price":0.39,"value":5850.0,"ownership":{"direct":true},"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001562180-22-001223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022001223/primarydocument.xml","form_type":"4"}},{"id":2517360,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-10T16:05:55.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying this option have vested."}],"balance_after":187286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-21-006964","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021006964/primarydocument.xml","form_type":"4"}},{"id":2517359,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T16:05:55.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":40000,"price":0.39,"value":15600.0,"ownership":{"direct":true},"balance_after":101000,"source":{"system":"sec-edgar","filing":"0001562180-21-006964","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021006964/primarydocument.xml","form_type":"4"}},{"id":2606925,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T20:58:17.000Z","date":"2021-08-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in thirty-six (36) equal monthly installments following the Grant Date."}],"balance_after":30000,"derivative":{"exercise_price":9.85,"expiration_date":"2031-08-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-21-003856","document":"form4-08112021_010801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588921003856/form4-08112021_010801.xml","form_type":"4"}},{"id":2633014,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":227286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633013,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":237286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633012,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-13","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":247286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633011,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-15","kind":"sale","acquired":false,"shares":10000,"price":18.4898,"value":184898.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $18.29 and a high of $18.64.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633010,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-15","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633009,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":10000,"price":19.0824,"value":190824.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price with a low of $18.90 and a high of $19.22.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633008,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-14","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633007,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":10000,"price":19.4536,"value":194536.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $19.25 and a high of $19.85.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2633006,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T16:01:39.000Z","date":"2021-07-13","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001562180-21-004949","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004949/primarydocument.xml","form_type":"4"}},{"id":2662967,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":257286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662966,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":267286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662965,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":277286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662964,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":10000,"price":21.7728,"value":217728.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $21.44 and a high of $21.92.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662963,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-17","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662962,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":10000,"price":21.7384,"value":217384.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price with a low of $21.55 and a high of $21.87.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662961,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-16","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662960,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":10000,"price":22.3909,"value":223909.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $22.10 and a high of $22.64.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2662959,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:05:43.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001562180-21-004348","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021004348/primarydocument.xml","form_type":"4"}},{"id":2696578,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-25T18:29:34.000Z","date":"2021-05-25","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying this option have vested."}],"balance_after":287286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-21-003737","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003737/primarydocument.xml","form_type":"4"}},{"id":2696577,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T18:29:34.000Z","date":"2021-05-25","kind":"exercise","acquired":true,"shares":20000,"price":0.39,"value":7800.0,"ownership":{"direct":true},"balance_after":61000,"source":{"system":"sec-edgar","filing":"0001562180-21-003737","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003737/primarydocument.xml","form_type":"4"}},{"id":2714012,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-13","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":307286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714011,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":317286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714010,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":327286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714009,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":10000,"price":20.5413,"value":205413.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $20.42 and a high of $20.895.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714008,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-13","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714007,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":10000,"price":20.0691,"value":200691.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price with a low of $19.80 and a high of $20.28.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714006,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-12","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714005,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":10000,"price":19.0997,"value":190997.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $18.69 and a high of $19.47.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2714004,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T16:43:50.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-003460","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021003460/primarydocument.xml","form_type":"4"}},{"id":2748317,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":337286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748316,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":347286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748315,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":357286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748314,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-15","kind":"sale","acquired":false,"shares":10000,"price":24.9631,"value":249631.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $24.62 and a high of $25.33.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748313,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-15","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748312,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":10000,"price":24.5272,"value":245272.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price with a low of $24.24 and a high of $24.81.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748311,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-14","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748310,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":10000,"price":23.8865,"value":238865.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $23.68 and a high of $24.05.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2748309,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T17:53:19.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021002835/primarydocument.xml","form_type":"4"}},{"id":2848938,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All shares underlying this option have vested."}],"balance_after":28393,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848937,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All shares underlying this option have vested."}],"balance_after":38393,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848936,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":11040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All shares underlying this option have vested."}],"balance_after":48393,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":11040},"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848935,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":10000,"price":26.0152,"value":260152.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price represents the weighted average price with a low of $25.88 and a high of $26.31.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 6 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848934,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":10000,"price":3.72,"value":37200.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848933,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":600,"price":28.41,"value":17046.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price represents the weighted average price with a low of $28.40 and a high of $28.42.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 5 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848932,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":9400,"price":27.5944,"value":259387.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $27.25 and a high of $28.21.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":41600,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848931,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":10000,"price":3.72,"value":37200.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848930,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":23,"price":37,"value":851.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848929,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2700,"price":36.215,"value":97780.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price with a low of $35.84 and a high of $36.785.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4."}],"balance_after":41023,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848928,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":8317,"price":34.8709,"value":290021.2753,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $34.71 and a high of $35.36.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":43723,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2848927,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T17:49:25.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":11040,"price":3.72,"value":41068.8,"ownership":{"direct":true},"balance_after":52040,"source":{"system":"sec-edgar","filing":"0001562180-21-001280","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021001280/primarydocument.xml","form_type":"4"}},{"id":2900337,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-21","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":59433,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900336,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-20","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":367286,"derivative":{"exercise_price":0.39,"expiration_date":"2024-05-09","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900335,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-20","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":69433,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900334,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-19","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":79433,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900333,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":10000,"price":20.64,"value":206400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $20.34 and a high of $20.94.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900332,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-21","kind":"exercise","acquired":true,"shares":10000,"price":3.72,"value":37200.0,"ownership":{"direct":true},"balance_after":51000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900331,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-20","kind":"exercise","acquired":true,"shares":4000,"price":0.39,"value":1560.0,"ownership":{"direct":true},"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900330,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":10000,"price":21.5107,"value":215107.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price with a low of $21.30 and a high of $21.74.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4."}],"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900329,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-20","kind":"exercise","acquired":true,"shares":10000,"price":3.72,"value":37200.0,"ownership":{"direct":true},"balance_after":47000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900328,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":10000,"price":20.8781,"value":208781.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average price with a low of $20.64 and a high of $21.35.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2900327,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-21T17:31:00.000Z","date":"2021-01-19","kind":"exercise","acquired":true,"shares":10000,"price":3.72,"value":37200.0,"ownership":{"direct":true},"balance_after":47000,"source":{"system":"sec-edgar","filing":"0001562180-21-000442","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218021000442/primarydocument.xml","form_type":"4"}},{"id":2939402,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-12-17T18:01:53.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":89433,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-007341","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218020007341/primarydocument.xml","form_type":"4"}},{"id":2939401,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-12-17T18:01:53.000Z","date":"2020-12-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":99433,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-007341","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218020007341/primarydocument.xml","form_type":"4"}},{"id":2939400,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-12-17T18:01:53.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":109433,"derivative":{"exercise_price":3.72,"expiration_date":"2025-12-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-007341","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218020007341/primarydocument.xml","form_type":"4"}},{"id":2939399,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-17T18:01:53.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":10000,"price":19.9668,"value":199668.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price represents the weighted average price with a low of $19.75 and a high of $20.22.  The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4."}],"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001562180-20-007341","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218020007341/primarydocument.xml","form_type":"4"}},{"id":2939398,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-17T18:01:53.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":10000,"price":3.72,"value":37200.0,"ownership":{"direct":true},"balance_after":47000,"source":{"system":"sec-edgar","filing":"0001562180-20-007341","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218020007341/primarydocument.xml","form_type":"4"}}],"next_cursor":"2020-12-17T18:01:53.000000Z,2939398"}